Report ID: SQMIG35A2516
Diabetic Retinopathy Market Size, Share, Growth Analysis, By Type(Proliferative Diabetic Retinopathy, and Non-proliferative diabetic retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35A2516 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
63 |
Figures:
75
Diabetic Retinopathy Market Regional Insights
North America dominated the market, accounting for 37.8% of total revenue in 2023. Some of the market's drivers include the presence of modern healthcare infrastructure, favorable government activities pertaining to medication research, and the presence of substantial patient & practitioner awareness levels. One of the primary factors contributing to this region's huge share is the high market penetration of new goods such as anti-VEGF medications such as Lucentis, Avastin, and Eylea. High healthcare expenditure, increased patient knowledge of diabetes, the availability of well-established medical facilities, and a favorable reimbursement environment are some of the primary causes.
The Asia Pacific market is expected to grow at a 7.1% CAGR from 2023 to 2030, owing to the presence of high unmet medical requirements, as well as rapidly rising patient awareness about effective diabetes diagnostic procedures and rising medical costs in the developing nations of India and China. Latin America and the Middle East are also expected to experience profitable growth during the predicted period.
Diabetic Retinopathy Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
